

# Annual Report 2021



**OSTEOARTHRITIS  
FOUNDATION  
INTERNATIONAL**

**OSTEOARTHRITIS FOUNDATION INTERNATIONAL**

---

C/ Tuset 19, 3<sup>o</sup>-2<sup>a</sup> · 08006 · BARCELONA

T.: +34 931 594 015

[www.oafifoundation.com](http://www.oafifoundation.com)

Version 01. March 2021

# Annual Report 2021

---

## CONTENT

1. OAFI'S PRESENTATION .....	3
1.1 Who we are.....	3
1.2 Osteoarthritis, a disease that affects all of us .....	3
2. STRATEGIC ACTIONS.....	4
2.1 Osteoarthritis International Association.....	4
3. SOCIAL ACTIVITIES .....	6
3.1 Conferences .....	6
3.2 Free consultations with patients .....	6
3.3 Symposium "Articulating Sport" .....	6
3.4 SEFAC Osteoarthritis Prevention Campaign - OAFI 2021.....	7
3.5 Supporting health authorities.....	7
3.6 Fira Gran.....	8
4. SCIENTIFIC RESEARCH.....	8
3.8 Cultural outings.....	9
4. SCIENTIFIC RESEARCH.....	10
5. SCIENTIFIC DISSEMINATION .....	12
5.1 Congresses and Conferences .....	12
6. COMMUNICATION AND AWARENESS.....	13
8. FINANCIAL STATEMENT.....	14

## 1. OAFI'S PRESENTATION

### 1.1 Who we are

The Osteoarthritis Foundation International (OAFI) is an independent non-profit foundation, that was created to prevent, treat and improve the quality of life of people suffering from osteoarthritis (OA) by providing them with the necessary tools to help them manage their disease. OAFI has its headquarters in Barcelona (Spain).

For this reason, the foundational activity focuses on the following activities:

- Increase social awareness about OA
- Improve the quality of life of patients and the prevention of risk groups (elderly people, sportspersons, postmenopausal women and children)
- Promote research in osteoarthritis and improve treatment

For us, patients are the most important.

### 1.2 Osteoarthritis, a disease that affects all of us

OA is a degenerative joint disease that affects the cartilage, bone and soft tissues of the joint. It produces pain and limits us when it comes to doing our daily tasks. It already **affects 500 million people in the world** according to the Lancet<sup>1</sup>. **Despite its enormous social impact, OA remains an unknown and distant disease for the majority of the population** and it is exclusively associated with elderly people. However, **it affects very fragmented groups of the population (elderly people, sportspersons, postmenopausal women and children)** who have very different needs and who cannot find an answer beyond a general approach.

---

<sup>1</sup> Osteoarthritis in 2020 and beyond: a Lancet Commission, Published Online November 4, 2020  
[https://doi.org/10.1016/S0140-6736\(20\)32230-3](https://doi.org/10.1016/S0140-6736(20)32230-3)

## 2. STRATEGIC ACTIONS

### 2.1 Osteoarthritis International Association

OAFI promotes the prevention, treatment, and improvement in the quality of life of OA patients by integrating all the agents involved in this pathology, including patients' associations, medical societies, research centres, public administrations, and collaborating companies to work together against this chronic disease.

At present, OAFI has signed agreements with different entities to collaborate in raising awareness of OA in the field of prevention and treatment of this disease.



OAFI leads this cluster of knowledge participated by interdisciplinary entities that work on the improvement of OA patients' quality of life. In 2021, 35 entities were working and collaborating.

The main role of each group:

#### a) Patient associations:

- a. Members work together in the dissemination and awareness of OA in society. Participants: Arthritis Foundation (USA), Pan-American League of Rheumatology Associations (PANLAR, representing the American continent), Liga Portuguesa Contra as Doenças Reumáticas (Portugal), Association

Francaise de Lutte AntiRhumatismale (France), Arthrose Fondation (Belgium), Associazione Nazionale Persone con Malattie Reumatologiche e Rare (APMARR, Italy), General Patients Association (AGP, Spain) and Spanish Association of Osteoporosis and Osteoarthritis (AECOSAR, Spain).

**b) Medical Societies:**

- a. It integrates relevant Spanish medical societies that have an important role in the care of patients with osteoarthritis, such as the Spanish Society of Rheumatology, Spanish Society of General and Family Doctors, Spanish Society of Primary Care Physicians, the Spanish Society of Traumatology in Sport, the Spanish Association of Community Pharmacies and The Spanish Society of Healthcare Quality.

**c) Research centres:**

- a. García Cugat Foundation, Drug Development Services at UB, Teófilo Hernando Foundation, Eurecat, Leitat, Poal Institute of Rheumatology, University of Barcelona (UB), CEMTRO Clinic, DKF Clinic, and the World Scleroderma Foundation (WSF) promote, in collaboration with OAFI, OA research initiatives in the field of medicine, sports medicine and nutraceuticals.

- d) Environment.** FC Barcelona, DiR Clubs, UBAE, Conex, Icaro Birding and Walkim Foundation give us support in the promotion of healthy joints and no pain.

### 3. SOCIAL ACTIVITIES

#### 3.1 Conferences

One of OAFI's priorities is to raise social awareness and conduct training courses for osteoarthritis patients and at-risk groups so that this disease is no longer unknown and associated with old age.

Due to the COVID-19 pandemic, the foundation was unable to carry out its regular activity. In 2021, OAFI was only able to hold one workshop:

- Joint pain workshop: osteoarthritis, Espai de la Gent Gran, Barberà del Vallès, 22 September 2021. Attendance 26 people

#### 3.2 Free consultations with patients

Patients with osteoarthritis are a priority for OAFI. That is why we offer free access to advise patients, mainly those with scarce resources. We listen to them, advise them and help them. In 2021, OAFI visited 520 patients who requested assistance and 120 referrals to doctors that collaborate with the Foundation.

In addition, we offered a nutritionist's service in which 15 people were visited and OAFI ran 5 online workshops with a total of 145 attendees.

#### 3.3 Symposium "Articulating Sport"

This annual event is dedicated to sport at amateur and professional levels to support all those who exercise to do so in optimal physical conditions.

It is common to see athletes who stress the body to the limit to obtain a high level of performance, especially in competitions. This practice increases the number of injuries and musculoskeletal disorders. It is also aimed at athletes with joint health problems such as patellar or patellofemoral chondromalacia, osteoporosis, pain, etc. to prevent and avoid a worsening of their condition.

The symposium aims to bring together all sports physicians, physiotherapists, coaches, psychologists, fitness and health professionals, athletes and students to raise awareness of the latest research results and practices from international experts.




In 2021, we had about 72 thousand views of the Symposium.

### 3.4 SEFAC Osteoarthritis Prevention Campaign - OAFI 2021

It is important to build awareness among patients because they play a key role in the prevention of joint health to delay or their deterioration.

For this reason, the OAFI foundation collaborated with the SEFAC Foundation in the informative campaign to raise awareness among the population through the community of pharmacists of the importance of improving joint health and preventing joint deterioration.



### 3.5 Supporting health authorities

The OAFI Foundation wants to be the voice of the patient and supports the health authorities in their action plans for the benefit of osteoarthritis patients. In this regard, the Foundation participated in the preparation of the Evaluation Report and Priority Lines of Action Strategy in rheumatic and musculoskeletal diseases of the National Health System.

OAFI also participated in the improvement of the Draft Decree of the Patients' Council of Catalonia to favour the participation of patients in the Catalan health system.

Finally, it is worth mentioning the appearance of the OAFI Foundation at the Health Commission of the Spanish Senate to present the current situation of osteoarthritis in Spain on September 28, 2021.



### 3.6 Fira Gran

OAFI participated in Fira Gran which was held from 27 to 29 October 2021. The event is a meeting point for specialised professionals and the seniors they attend. This year there were about 40,000 visitors. About 1,000 people visited the OAFI Foundation exhibit.



### 3.7 V International Congress of patients with osteoarthritis

OAFI organises an international congress of osteoarthritis patients every year. The purpose of this public event is to provide a forum for the exchange of knowledge and social awareness. The event is aimed at osteoarthritis patients and risk groups (elderly, athletes and post-menopausal women) to improve their quality of life.

The event took place in site with 400 attendees and was later broadcast online through our YouTube Channel.

In 2021, the congress was attended by health authorities, international experts, patient associations, medical societies, health professionals (pharmacists, physiotherapists and social workers) and representatives of sports clubs, among others. Scientific publications were presented, round tables were held to discuss osteoarthritis, patients participated and the role of medical agencies was discussed.





In addition, because two out of three osteoarthritis patients are women, this congress had a special focus on women.

The day before, we organized the Pre Congress Day with the participation of prestigious international scientists, as well as leading scientific journals.



### 3.8 Cultural outings

At OAFI we encourage osteoarthritis patients to be active, move around and socialize. We want them to get out of the house. For this reason, at the end of 2021, we were able to organize a cultural outing with patients. We went to the theatre to see " The House of the Spirits" at the Romea theatre on 10 November 2021. Twelve people were in.

## 4. SCIENTIFIC RESEARCH

### Our projects presented

- **CAVIPA Study - Survey on the Quality of Life of Osteoarthritis Patients.** Analysis of the perception of the quality of life of patients with knee and/or hip osteoarthritis and its associated factors. The first survey was made in Spain to evaluate the quality of life as an indicator to be included in osteoarthritis treatment programs.
- **ODPAR Study. Care Pathway for Osteoporosis Patients.** Evaluation of medical care, experience, needs and quality of life of patients with osteoporosis.
- **Osteomuscular and Rheumatologic Pain - Evidence on the use of topical diclofenac and CBD.** Literature review on the topical use of diclofenac and CBD.
- **Efficacy and Safety of Arthrodesmol for Assessing improvement of symptomatic osteoarthritis of the knee.** In this routine clinical experience, we wanted to confirm the efficacy and safety of intra-articular infiltration of Arthrodesmol for patients with osteoarthritis of the knee.
- **SYSADOAs: do their origin and quality make a difference in efficacy and safety?** Differences in the regulation of pharmaceutical and nutraceutical grade products cause variations in quality and content (chondroitin sulfate, glucosamine and diacerein). A literature review has been conducted on the variations in extraction and purification techniques that can lead to differences in content, composition, purity, biological effects, safety, and quality. The study was published in Global Rheumatology, March 24, 2021, PANLAR.

### Our ongoing R&D projects

- **Clinical trial for a new dietary supplement treatment of knee osteoarthritis in the sports population.** OAFI is co-promoter of the study in which we offer advice for the benefit of the patient. Ongoing study
- **Clinical trial for the treatment of a type of hand osteoarthritis.** OAFI is co-promoter of the study in which we offer advice for the benefit of the patient. Ongoing study
- **Clinical practice study with chitosan derivatives in patients with severe knee pain.** OAFI is co-promoter of the study in which we offer advice for the benefit of the patient. Ongoing study
- **Preventomics.** Biomarker-based system to send personalized advice on dietary and lifestyle habits to empower consumers to prevent diet-related diseases. OAFI is in charge of disseminating the results of the project to the scientific community and consumers. To this end, OAFI participates in international congresses and symposia to present PREVENTOMICS and make the results public to society.

- **TriAnkle.** Bioimpresión personalizada para la regeneración del tendón. Nuestra investigación se centra en mejorar la vida de los pacientes. Nuestro objetivo es desarrollar un tratamiento innovador para millones de pacientes de todo el mundo que sufren tendinopatías y artrosis, un problema de salud que afecta especialmente a las personas mayores, las mujeres y a los deportistas profesionales. OAFI tiene un papel activo desde la perspectiva de los pacientes participando en las tareas de ética y regulatorio, involucración de los pacientes y calidad de vida. Además, colaboramos en la divulgación de los resultados.

## 5. SCIENTIFIC DISSEMINATION

### 5.1 Congresses and Conferences

OAFI is concerned about the need for being involved in scientific dissemination in the field of OA. For this reason, OAFI participated in the following events:

- **OA Working Group:** Elevating the Hidden Cost of Osteoarthritis Pain in the EU, online, Pfizer, 20 April 2021
- **CINFA Professional Meeting,** Laboratorios CINFA, Spain, 4 May 2021
- **EULAR Congress Online,** June 1-4, 2021
- **Farmaindustria - Patient Organizations Dialogue,** Online Meeting, Foro de Pacientes, Spain, 30 June 2021
- **Pain in Community Pharmacy,** FAES Farma headquarters, 6 July 2021
- **IX FTYS Online Meeting,** Foro de Pacientes, Spain, 13 July 2021
- Online conference. **Immunological therapies, a new opportunity to fight diseases,** Bamberg Foundation, 6 September 2021
- **Joint Challenge 2021,** Cernobbio, Italy, 15-16 October 2021
- **AEA SEROD Congress,** Palma de Mallorca, Spain, 22 September 2021
- **58th SECOT Congress,** Seville, Spain, 29 September-October 1, 2021
- **43rd SEMERGEN National Congress,** Zaragoza, Spain, from 29 to – 2 October 2021
- **Bamberg Summit,** online, 25 October 2021
- **V Spanish Patients' Forum (FEP) Meeting,** online, 27-28 October 2021
- **I Course on Osteoarthritis of the Spanish Society of Rheumatology,** online, 19-20 November 2021
- **25th Anniversary of the Teófilo Hernando Foundation,** Madrid, Spain, 2 December 2021

## 6. COMMUNICATION AND AWARENESS

The following is OAFI media coverage in 2020:

### Press:

- General: El País, El Periódico, La Razón, La Vanguardia, ABC, El Punt Avui, 20 minutes ...
- Specialised: ConSalud, Sanifax, Redación Médica, Infosalus ...

### Radio:

- RNE, OndaCero, Cope, Rac1, Catalunya Radio

### TV:

- TeleMadrid

### Online:

- + 1M OAFI impressions on the Internet by 2020
- 183,500 impressions on Twitter
- 15,715 impressions on Facebook
- 2,071 unique users reached on Instagram
- 658 Visiting users on our LinkedIn page
- 742,614 views on our YouTube Channel
- 103,205 visits to our website

## 8. FINANCIAL STATEMENT

### INCOME STATEMENT

INCOME STATEMENT (IN EUROS)	2021
<b>1. Ordinary Income</b>	<b>538.167,86</b>
a) Sales and provision of services	166.981,84
b) Income received on a regular basis	0,00
c) Income from promotions, sponsors and collaborations	231.400,00
d) Subsidies, donations and bequests received in the fiscal year	139.786,02
<b>2. Subsidies granted and other expenses</b>	<b>0,00</b>
a) Subsidies granted	0,00
b) Expenses for collaborations and for acting as member of the board of directors	0,00
<b>3. Variation in stocks of finished and semi-finished goods</b>	<b>0,00</b>
<b>4. Work carried out by the entity for its assets</b>	<b>0,00</b>
<b>5. Supplies</b>	<b>-86.867,58</b>
<b>6. Other operating income</b>	<b>0,00</b>
a) Income from lease	0
b) Other income from accessories and other current activities	2
<b>7. Wage and Salary expenses</b>	<b>-304.764,97</b>
<b>8. Other Operating Expenses</b>	<b>-97.646,93</b>
a) External Services	-97.642,44
a1) Research and development	0,00
a2) Lease and fees	-24.105,05
a3) Repairs and maintenance	-137,83
a4) Independent professional services	-25.173,75
a5) Transport	0,00
a6) Insurance premium	-403,48
a7) Banking services	-871,16
a8) Advertising, promotion and public relations	-530,23
a9) Supplies	-2.698,68
a10) Other services	-33.495,43
a11) Travel and accomodation allowances	-9.485,73
a12) Non-deductible expenses	-741,10
b) Taxes	0,00
c) Losses, impairment and variation of provisions for operations of the activities	0,00
d) Other operating expenses	-4,49
<b>9. Depreciation expense</b>	<b>-3.574,65</b>
<b>10. Subsidies, donations and bequests transferred to income in the fiscal year</b>	<b>0,00</b>
<b>11. Surplus provisions</b>	<b>0,00</b>
<b>12. Deterioration and result due to alienation of fixed assets</b>	<b>0,00</b>
<b>13. Other results</b>	<b>0,00</b>
<b>I) GROSS OPERATING PROFIT (1+2+3+4+5+6+7+8+9+10+11+12+13)</b>	<b>45.313,73</b>
<b>14. Interest revenue</b>	<b>0,00</b>
<b>15. Interest expense</b>	<b>0,00</b>
<b>16. Reasonable value variation on financial instruments</b>	<b>0,00</b>
<b>17. Exchange rate differences</b>	<b>0,00</b>
<b>18. Deterioration and result due to alienation of financial instruments</b>	<b>0,00</b>
<b>II) FINANCIAL RESULT (14+15+16+17+18)</b>	<b>0,00</b>
<b>III) INCOME BEFORE TAXES (I+II)</b>	<b>45.313,73</b>
<b>19. Income tax</b>	<b>0,00</b>
<b>IV. NET PROFIT (III + 19)</b>	<b>45.313,73</b>

## BALANCE SHEET

<b>ASSETS</b>	<b>2021</b>
<b>A) NON-CURRENT ASSETS</b>	<b>22.123,99</b>
I. Intangible assets	0,00
III. Tangible fixed assets	16.799,82
V. Long-term investments in companies and entities of the group and associate:	0,00
VI. Long-term financial investments	3.580,00
VII. Deferred tax assets	1.744,17
<b>B) CURRENT ASSETS</b>	<b>178.420,76</b>
I. Stocks	0,00
II. Users, Sponsors and debtors of activities and other accounts receivable	17.040,75
1. <i>Users and debtors from sales and provision of services</i>	6.050,00
2. <i>Debtors, entities of the group and associates and other related parties</i>	-5,00
3. <i>Sponsors</i>	0,00
4. <i>Other debtors</i>	10.995,75
5. <i>Staff</i>	0,00
6. <i>Assets for current tax and other credits with public administrations</i>	0,00
7. <i>Founders and partners for pending disbursements</i>	0,00
III. Investments in short-term companies and group entities and associates	247,13
IV. Short-term financial investments	0,00
V. Short-term accruals	0,00
VII. Cash and other equivalent liquid assets	161.132,88
<b>TOTAL ASSETS (A + B)</b>	<b>200.544,75</b>

<b>LIABILITIES</b>	<b>2021</b>
<b>A) SHAREHOLDERS' EQUITY</b>	<b>90.539,33</b>
<b>A1) Capital Stock</b>	<b>90.539,33</b>
I. Endowment funds or social funds	30.000,00
1. Endowment funds or social funds	30.000,00
2. Endowment funds or social funds pending disbursement	0,00
II. Special funds	16.502,40
III. Retained earnings from previous years	-1.278,80
IV. Surpluses pending application in statutory activities	0,00
V. Retained earnings from last year	45.315,73
VI. Contributions to compensate losses	0,00
<b>A-2) Subsidies, donations and bequests received and other adjustments</b>	<b>0,00</b>
1. Official capital subsidies	0,00
2. Capital donations and bequests	0,00
3. Other grants, donations and bequests	0,00
4. Fiscal revenues to be distributed	0,00
<b>B) NON-CURRENT LIABILITIES</b>	<b>0,00</b>
I. Long-term provisions	0,00
II. Long term debts	0,00
1. Debts with credit institutions	0,00
2. Other long-term debts	0,00
III. Long-term debts with entities of the group and associates	0,00
IV. Deferred tax liability	0,00
V. Long-term accruals	0,00
<b>C) CURRENT LIABILITIES</b>	<b>110.005,42</b>
<b>I. Short-term provisions</b>	<b>0,00</b>
<b>II. Short term debts</b>	<b>3.116,63</b>
<b>III. Short-term debts with entities of the group and associates</b>	<b>0,00</b>
<b>IV. Creditors for activities and other accounts payable</b>	<b>23.072,29</b>
1. Suppliers	0,00
2. Creditors	23.072,29
3. Staff (salaries pending payment)	0,00
4. Liabilities for current taxes and other debts with public administrations	0,00
5. Down payments of users	0,00
<b>VII. Short-term accruals</b>	<b>83.816,50</b>
<b>TOTAL LIABILITIES (A + B + C)</b>	<b>200.544,75</b>